Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
Dehydration, dizziness, rashes, itching, and facial swelling are also potential long-term symptoms to be cautious of
Semaglutide begins working right away to suppress appetite and slow gastric emptying, but measurable weight loss usually becomes noticeable after the first 24 weeks
Retrieved August 21, 2025, from Bozick, R., Donofry, S
Patients can reduce symptoms by eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated
